Advertisement
As of 12:34PM EST. Market open.
| Previous Close | 2.9800 |
| Open | 3.0500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.8000 - 3.0800 |
| 52 Week Range | 1.3000 - 3.7100 |
| Volume | |
| Avg. Volume | 28,812 |
| Market Cap | 49.386M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
Simply Wall St.Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Exagen ( NASDAQ:XGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$12.5m (down 6.8% from 3Q 2023). Net...
GlobeNewswireExagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune diseaseCARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve th
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.